Connect with us

Press Release

China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type

Published

15 hours ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement  (the “Agreement”)  with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or  the “Product”)  for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party.

 

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety profile to improve compliance of patients and therefore brings clinical benefits.

 

CMS has rooted in the central nervous system therapeutic fields for years, continuously deploying and developing global differentiated and innovative products to strengthen its competitiveness in its advantageous specialty therapeutic fields. ZUNVEYL will further diversify our Group’s innovative drug product matrix and synergize with various central nervous system products including the marketed innovative drug VALTOCO (diazepam nasal spray), the original branded drug Deanxit (flupentixol and melitracen tablets) and the innovative pipeline drug Y-3 injection (a novel brain cytoprotectant that treats stroke). Leveraging its proven clinical development capability and compliant commercialization system with high efficiency, CMS will promote the approval of ZUNVEYL in China as soon as possible to bring a new drug option for the treatment of cognitive impairment in Alzheimer’s disease patients.

 

About ZUNVEYL

ZUNVEYL was approved in July 2024 by the U.S. FDA. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients.

 

As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. Patent in regard to use of ZUNVEYL has already been granted in China.

 

About Alzheimer’s disease

Alzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.

 

Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, suggesting that Alzheimer’s disease patients still have an urgent need for safer therapies.

 

About ALPHA

Alpha is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive impairment with mild Traumatic Brain Injury. On July 2024, Alpha received approval by the FDA of its New Drug Application (NDA) for ZUNVEYL for the treatment of mild-to-moderate Alzheimer’s disease. Alpha will now focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation. Additionally, Alpha has three pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation for the treatment of mild-to-moderate Alzheimer’s disease, ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild Traumatic Brain Injury. For more information about Alpha and its pipeline, please visit: https://www.alphacognition.com/ .

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Reference:

  1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.0000000000011832
  2. Safety profile of ZUNVEYL as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-ther…
  3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.003
  4. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer’s Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.004
  5. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-7
  6. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.
  7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-diseas…
  8. Research Report on the Diagnosis and Treatment of AD Patients in China (2020). Alzheimer’s Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg202…

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

New Study Reveals U.S. States with the Highest and Lowest Substance Abuse Rates

Published

30 minutes ago

on

January 9, 2025

By

United Kingdom — When relocating to a new state, factors like school quality, healthcare access, and crime rates often play a significant role in decision-making. However, one critical factor frequently overlooked is the prevalence of substance abuse, a crisis that not only impacts individuals but also disrupts entire communities.

In a recent study, analysts at Pink Storage examined substance abuse rates across the United States, highlighting states with the highest and lowest levels of drug and alcohol misuse.

Key Findings:

States with the Highest Levels of Substance Abuse:

  • Tennessee
  • Ohio
  • Oregon
  • Vermont
  • Arizona

States with the Lowest Levels of Substance Abuse:

  • Texas
  • Georgia
  • Florida
  • North Carolina
  • Utah

States with the Highest Fatal Overdose Rates (per 100,000 people):

  • West Virginia (80.9)
  • Tennessee (56)
  • Delaware (55.3)
  • Louisiana (54.5)
  • Maine (54.3)

States with the Fewest Fatal Overdose Rates (per 100,000 people):

  • South Dakota (11.3)
  • Nebraska (11.8)
  • Iowa (15.3)
  • Texas (18.2)
  • Hawaii (18.6)

Drug-Specific Trends:

Cocaine Usage:

  • Highest Prevalence: Colorado (6.49%)
  • Lowest Prevalence: Arkansas (2.44%)

Marijuana Usage:

  • Highest Prevalence: Vermont (53.77%)
  • Lowest Prevalence: Utah (25.32%)

Excessive Alcohol Consumption:

  • Highest Prevalence: Vermont (42.43%)
  • Lowest Prevalence: Utah (16.95%)

Alcohol-Related Deaths (per 100,000 people):

  • Highest: New Mexico (99)
  • Lowest: Utah (32)

A full study with methodology can be found here.

A Call for Awareness and Support

A spokesperson from Pink Storage commented on the findings:

“The study shows that all areas of the United States suffer from some form of substance abuse, and if you or someone you know are suffering, it’s important to reach out and get treatment.”

“Delaying treatment can put you at risk for fatal consequences, and if no action is taken, addiction can become more severe. Substance use disorders won’t get better on their own, and rehab offers a chance for recovery. Rehab can eliminate physical dependence while addressing the psychological side of addiction.”

Substance abuse remains a nationwide challenge, but with greater awareness, accessible treatment options, and community support, meaningful change is possible.

About Pink Storage:

Pink Storage is a self-storage company in the UK that offers affordable self-storage. They also create data-backed studies that can help you when choosing to move into an area.

Media Contact:

Company Name: Pink Storage

Contact Person: Scott Evans, Managing Director

Email: info@pinkstorage.co.uk

Phone: 08003134401

Website: pinkstorage.co.uk

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Dr Robert Becker Clinic Celebrates Patient Satisfaction Win at Mental Health Care Awards by Business Awards UK

Published

2 hours ago

on

January 9, 2025

By

Edinburgh, United Kingdom, 9th Jan 2025 – The Dr Robert Becker Clinic has been honoured with the Patient Satisfaction Award at the 2024 Mental Health Care Awards hosted by Business Awards UK. This accolade recognizes the clinic’s dedication to delivering personalised, patient-centred care and its commitment to excellence in the field of mental health. 

Located in Edinburgh, the Dr Robert Becker Clinic has established itself as a leader in mental health treatment, offering a comprehensive range of services tailored to individual needs. Under the expert guidance of Dr Robert Becker—a distinguished Psychotherapist, Neuropsychologist, Cognitive Psychologist, and Pharmacologist— the clinic adopts a holistic approach to mental health, ensuring that each patient receives personalised and compassionate care. 

At the heart of the clinic’s success is its founder, Dr Robert Becker, whose credentials include a PhD in Social Sciences specialising in Cognitive Psychology. Dr Becker is also a Practising Fellow of the Complementary Medical Association, with extensive qualifications including advanced certifications in CBT, Neuropsychology, and Addiction Therapy, alongside expertise in managing complex conditions such as ADHD, insomnia, and substance misuse.

 

 

The clinic adheres to rigorous diagnostic standards, employing methodologies compliant with ICD-11 and DSM-5 to ensure precision in assessment and effectiveness in treatment. 

Dr Robert Becker’s patient-first philosophy is central to the clinic’s reputation. By offering consultations in English and Polish and tailoring therapies to individual needs, the clinic has garnered a loyal following, consistently ranked as the number one mental health specialist in Edinburgh.

The clinic’s comprehensive suite of services includes: 

Psychiatric Assessments: Utilising evidence-based tools like the MPAS system for accurate evaluations. 

Therapy for All Ages: Addressing challenges ranging from anxiety and depression to ADHD and sleep disturbances.

Specialist Care: Providing second opinions and consultations on complex cases.

Winning the Patient Satisfaction Award highlights the clinic’s commitment to achieving the best outcomes for its patients. The accolade underscores not only the clinic’s exceptional care but also its innovative practices, which include advanced approaches like the CAMS method for managing suicide risk. 

As Dr Becker continues to expand his contributions to the field, including authoring a book on Behavioural Analysis and Forensic Psychology, the clinic remains at the forefront of mental health care in the UK.

The Dr Robert Becker Clinic sets an example in mental health care, blending science with compassionate, personalised services. This recognition at the 2024 Mental Health Care Awards is a testament to the clinic’s commitment to helping patients and advancing mental health care.

To find out more about the Dr Robert Becker Mental Health Clinic and Educational Centre and their award win, visit their website, or contact Business Awards UK. 

About Dr Robert Becker Clinic 

The Dr Robert Becker Clinic, based in Edinburgh, is a leading provider of comprehensive mental health care. Founded by the esteemed Dr Robert Becker—an expert in Psychotherapy, Neuropsychology, Cognitive Psychology, and Pharmacology—the clinic is dedicated to delivering personalised, patient-centred care. With a strong focus on holistic treatment approaches, the clinic addresses a wide spectrum of mental health challenges, including anxiety, depression, ADHD, insomnia, and substance misuse. 

About Business Awards UK:

Business Awards UK is an awards platform with a big mission: making business awards accessible to all. With no upfront costs for entry, we’ve removed the risk and lowered the barrier to entry for everyone, because this is the change we wanted to see in the business awards arena.

Media Contact

Organization: Dr Robert Becker Mental Health Clinic & Educational Centre Ltd

Contact Person: Dr Robert Becker, Director

Website: https://www.rbecker-mhs.co.uk/

Email: edinburgh@rbecker-mhs.co.uk

Contact Number: +441315163360

City: Edinburgh

Country: United Kingdom

Release Id: 09012522330

The post Dr Robert Becker Clinic Celebrates Patient Satisfaction Win at Mental Health Care Awards by Business Awards UK appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Winners and Finalists Announced for BREW Readers Choice Award 2024-2025

Published

3 hours ago

on

January 9, 2025

By

Australia, 7th Jan 2025, –
 

The Chrysalis BREW Project has announced the winners and finalists of the 2024-2025 BREW Readers’ Choice Award. This award highlights books that have garnered the highest recognition from readers worldwide. Books that receive at least 4 out of 5 stars in their BREW reviews are automatically shortlisted for the monthly and annual titles. The accolades include a Book of the Year title, an Honourable Mention, Book of the Month accolades, a list of outstanding finalists, and a Publisher of the Year title.

The 2024-2025 Book of the Year is “Unheard” by Bhavini Bhargava, which received over 10,000 votes. The Honourable Mention was awarded to “My Lost Pages” by Sneha Sabu, securing more than 4,000 votes.

Esperanza Pretila, founder of The Chrysalis BREW Project, stated that “the awards underscore the importance of reader engagement in celebrating literary works that resonate globally.” She also expressed gratitude to all participants who supported their favourite books and authors.

This year’s awards reflect a broad spectrum of literary voices and themes, showcasing books that have captured the hearts of readers worldwide.

THE HONOUREES

Here are the complete lists of winners:

BREW Readers’ Choice Award Book of the Year: “Unheard” by Bhavini Bhargava

BREW Readers’ Choice Award Honourable Mention: “My Lost Pages” by Sneha Sabu

BREW Readers’ Choice Award 2024-2025 Finalists:

  1. “The Velvet Hammer” by Chief Justice Belvin Perry, Jr. and Amy Mitchell
  2. “Merely Mortal” by Michelle M. Pillow
  3. “Always Haunted: Hallowe en Poems” by LindaAnn LoSchiavo
  4. “The Butcher and the Bard” by J. E. Harter
  5. “Bunky and the Summer Wish” by Aleksandra Tryniecka
  6. “Saint Bloodbath” by Frederick Douglass Reynolds
  7. “Covered in Flour” by Charles Presti
  8. “Deception Bay” by N N Parker
  9. “Fiercely ME” by Stephanie Rowe
  10. “Grasslands” by Shekhar Khatri
  11. “Heir to the Ice Flame” by Rose Harvey
  12. “The Ghost in the Garden” by Alisse Lee Goldenberg
  13. “Werecats Emergent” by Mark J. Engels
  14. “No Going Back” by Susan Frances
  15. “The Spirituality in Science” by Benneth Iwuchukwu
  16. “Six Moons, Seven Gods” by Robert A. Walker
  17. “Harvest Cruise” by Rebecca Benison
  18. “Killing Shore” by K.A. Nelson
  19. “Building a Team: A Baseball Buddies Story” by Aaron Derr
  20. “My Unexpected Life: Finding Balance Beyond My Diagnosis” by Jennifer Gasner
  21. “Goyhood” by Reuven Fenton
  22. “Why in the World Are We Here?” by Clare-Rose Trevelyan
  23. “The Retirement Planning Roadmap” by Sweet Home Publishing
  24. “Of Friction” by S. J. Lee
  25. “Your Forgotten Sons” by Anne Montgomery
  26. “Glitches of Gods” by Jurgen “Jojo” Appelo
  27. “You Are There” by Felicity Wrangles
  28. “Until the Stars Align” by Carolyn Summer Quinn
  29. “The Street Between the Pines” by J.J. Alo
  30. “Bereft: A Story about Love, Loss, and Family” by M. A. Quigley
  31. “May I Come to Your Party?” by Grace A. Wolf
  32. “Belle And Chloe: Reflections In The Mirror” by Isabela Sardas, Ph.D.
  33. “A Different Lens” by Sheila Eve Arad
  34. “Things to Aim For” by Rodney Ross
  35. “I’m Beautiful Because I Am” by Azizi Tuere
  36. “The Treasure of Tundavala Gap” by Jeffrey K. Schmoll
  37. “Dreams and Metamorphoses” by Fabio Grandi
  38. “The Lilacs I Once Knew: Friddie’s Poems” by Roni Rosenthal
  39. “The Meaning of Okay” by Cortney Raymond
  40. “Journey of a Radiant Heart” by Niomi Nicci
  41. “Guilty of Stealing His Heart” by Nancy Lynn White
  42. “The Adventures of Angel” by Ross Alan Hahn
  43. “The Love Tank” by Andrea Mendoza-Vasconez
  44. “Circus Home: A Novel of Life, Love and New Jersey” by Jason Ollander-Krane
  45. “The Secret Life of Bears” by Joann Slead
  46. “Here There Be Monsters” by Josh Wright
  47. “My Place Among Them” by J. Stanion
  48. “Thomas the Terrible Tomcat Needs a Friend” by Zivile Cecilia Brubeck
  49. “The Soul Sistas Go To School!: (Too Cool for School?)” by Newton Vanriel
  50. “New American Monarch” by Marcel Fable Price
  51. “Rock, Crush and Roll” by Hunter Snow
  52. “A New Family for Tate” by Erika L. Turner, LCSW
  53. “The Only Anxiety Book for Teens You Will Ever Need” by Carla Picolli
  54. “Nature Ninja Saves the Natural World” by Tania Moloney
  55. “The First Unicorn” by Kathleen J. Shields
  56. “AI… Meets… AI” by Amber Ivey
  57. “The Bravest Soldiers” by Elaine Schroller
  58. “Praesidium” by McKinley Aspen
  59. “Cogitatio: Shadows in the Wind – Book Two” by McKinley Aspen
  60. “Facts Are Stubborn Things” by Richard A Danzig
  61. “Sentience Hazard” by Alexandru Czimbor
  62. “Emma’s Fury” by Linda Rainier
  63. “Believe Nothing, Know Nothing” by Jean-Claude Koven
  64. “Until September” by Harker Jones
  65. “Adventures of Fairies and Dragons” by Nancy Benson
  66. “Daughters of Green Mountain Gap” by Teri M. Brown
  67. “Fabric of Light” by Travis Sharp
  68. “Jar of Tears” by Kathleen Templeton
  69. “The Serpent’s Tongue (Nova 02)” by C. T. Emerson
  70. “Intrepid Spirit” by David Tunno
  71. “Taking Flight” by Jacques Sardas
  72. “Dreams and Illusions” by Rebecca Olmstead
  73. “Wayward Wings” by S. Slottje
  74. “Golden” by S.S. Turner
  75. “Punch Line” by Richard A. Danzig
  76. “Luck and Love in 1902” by Jody Gorran
  77. “Olympus Bound” by Zoë Routh
  78. “No Borders for Truth” by Martin J. Brown
  79. “Ain’t No Jazz in Kansas City” by Bruce Rodgers
  80. “The Sound of an Ordinary Life” by Alis Cerrahyan
  81. “Rogues of the Crosslands: Azoria’s Blade” by John Daze
  82. “Bad Love Medicine” by Kevin Schewe M.D.
  83. “The Bright Freight of Memory” by Greg Fields
  84. “Vermilion Harvest” by Reenita M. Hora
  85. “Ghost Train” by Natalie Anna Jacobsen
  86. “Navigating Life’s Challenges” by Luminescence Goh
  87. “The Ultimate Guide to Rapport” by Stig Ernsund
  88. “Nate’s Noisy Nose” by Frances Mackay
  89. “The Great Christmas Escape” by Janae Haddad
  90. “The Lonely Prisoner” by Michael J. Kundu
  91. “Black On Madison Avenue” by Mark S. Robinson
  92. “Me Power” by LaNysha T. Adams
  93. “The Stress Book: Forty-Plus Ways to Manage Stress & Enjoy Your Life” by D. Terrence Foster MD
  94. “The Matters of Friendship” by Rona D. Drinkard
  95. “Hatfield 1677” by Laura C. Rader
  96. “Lasting Transformation: A Guide to Navigating Life’s Journey” by Abby Rosen PhD
  97. “Run for My Life” by Joseph P. Odonnell
  98. “Muddy the Water” by Jessica Barrows Beebe and Matt Barrows
  99. “Delaware Before the Railroads: A Diamond Among the States” by Dave Tabler
  100. “Fever of Unknown Origin” by Judith Ford
  101. “Soul Threads” by Camilla Fellas Arnold

 BREW Readers’ Choice Award Book of the Month Winners

  1. December 2024 – No winner
  2. November 2024 – “Building A Team: A Baseball Buddies Story” by Aaron Derr
  3. October 2024 – “Harvest Cruise” by Rebecca Benison
  4. September 2024 – “Unheard” by Bhavini Bhargava
  5. August 2024 – “Saint Bloodbath” by Frederick Douglass Reynolds
  6. July 2024 – “My Lost Pages” by Sneha Sabu
  7. June 2024 – “Six Moons, Seven Gods” by Robert A. Walker
  8. May 2024 – “The Spirituality in Science” by Benneth Iwuchukwu
  9. April 2024 – “No Going Back” by Susan Frances
  10. March 2024 – “The Ghost in the Garden” by Alisse Lee Goldenberg
  11. February 2024 – “Werecats Emergent” by Mark J. Engels
  12. January 2024 – no winner

Selection for the BREW Readers’ Choice Award 2024-2025 Publisher of the Year title is still ongoing. The free-for-all global public voting officially opens on 31 January 2025. Early voting access options and real-time tracking of results are also available from 9 January 2025. More details can be accessed through the following link: https://thechrysalisbrewproject.com/2025/01/09/🎉-public-voting-for-the-brew-readers-choice-award-2024-2025-publisher-of-the-year-opens-soon-🎉/. 

For more information about the announcement and BREW Readers’ Choice Award, visit The Chrysalis BREW Project.

ABOUT THE BREW READERS’ CHOICE AWARD

Unlike the other BREW Book Awards that involve judges’ assessments, the BREW Readers’ Choice Award is a reader-driven literary accolade that celebrates exceptional books chosen by public vote. Monthly winners automatically qualify for the annual awards. The initiative highlights the connection between readers and the books they love, fostering a global community united by a shared appreciation for literature.

Nominations are now open for the 2025 round of the award. To nominate or for more information on the award, please visit https://thechrysalisbrewproject.com/the-brew-awards/.

ABOUT THE CHRYSALIS BREW PROJECT

The Chrysalis BREW Project is dedicated to recognising and promoting excellence in literature. Through its diverse awards, the project aims to empower authors, celebrate literary achievements, and connect readers worldwide with meaningful stories.

 

Media Contact

Organization: The Chrysalis BREW Project

Contact
Person: The Chrysalis BREW Project

Website:

https://thechrysalisbrewproject.com

Email:

info@thechrysalisbrewproject.com

Country:Australia

The post Winners and Finalists Announced for BREW Readers Choice Award 2024-2025 appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us